Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Korean men and women aged 20 years or more~* Presence of pain associated with a spinal disease and lumbar fusion at 1-2 spinal segments (1-2 level lumbar fusion surgery)~* Moderate to severe pain of the NRS pain score ≥ 4 at Visit 1 (14\~90 days after surgery, Baseline) (Amended 21Nov2013)~* Consent to participate in the study and voluntary signature on the informed consent form~Exclusion Criteria:~* Women of childbearing potential, except for the following cases:~* A partner who is vasectomized or otherwise surgically sterile.~* Use of 2 contraception methods. Two methods include the combination of double-barrier contraception or barrier contraception and hormone contraception, and appropriate barrier methods are as follows: Diaphragm (female contraceptive device), condom, intrauterine (copper or hormone), sponge or spermicide. Hormonal contraceptives include all commercially available products containing estrogen and/or progesterone.~* Pregnant or breastfeeding women. Pregnant woman is defined as a woman after fertilization to late pregnancy with a positive result from the urine pregnancy test.~* History of hypersensitivity to buprenorphine, tramadol, APAP or excipients, and celecoxib~* Medical history of asthma, acute rhinitis, nasal polyp, vascular edema urticaria or allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs(NSAIDs, COX-2)~* Hypersensitivity or intolerance to Domperidone~* Risk of gastrointestinal irritation such as gastrointestinal bleeding, mechanical ileus or perforation~* Genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption~* Severely impaired respiratory function or respiratory depression~* Current use of monoamine oxidase(MAO) inhibitors or the medication history within 2 weeks prior to study participation~* Convulsive disorder, head injury, shock, decreased level of consciousness of uncertain origin, intracranial lesion or increased intracranial pressure or severe hepatic impairment~* Biliary tract disorder~* Presence or suspected drug abuse history~* Medical history of opioid or drug dependence~* Current use of other CNS inhibitors or muscle relaxants that may result in dyspnea, hypotension, severe sedation or coma when used with the investigational product, opioid analgesics~* Use of strong opioids, buprenorphine or tramadol/APAP within 1 week prior to study participation (however, study participation is allowed for PRN prescription of PCA and strong opioids)~* Any condition representing a contraindication of application of buprenorphine, tramadol/APAP or celecoxib~* Major pain not attributable to a spinal disease~* Anticancer therapy that may affect pain assessment~* Clinically significant cardiovascular or renal dysfunction~* Postoperative complications~* Symptoms of acute pain after lumbar fusion or characteristic analgesic features showing rapidly changing needs for analgesics~* Current use of other investigational product at enrollment or within 30 days after administration of other investigational product

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- buprenorphine (Type: EXPERIMENTAL): Patch
- tramadol/acetaminophen (Type: ACTIVE_COMPARATOR): Oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).